Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

th weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat-dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at http://www.schering-plough.com.

About Schering-Plough

Schering-Plough is a
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.C. , April 24, 2015  New ... ability of consumers to educate themselves about products ... the tools and techniques available to market researchers ... the changing consumer marketplace, it,s imperative that organizations ... to better identify market opportunities, niches and growth ...
(Date:4/24/2015)... 24, 2015   Vestagen Technical Textiles, Inc. ... , has recently received two notable innovation awards. The ... that recognizes innovations with potential to create a positive ... in New York City , VESTEX ... "Protection & Safety" category. The awards honor excellence in ...
(Date:4/24/2015)... Boston Scientific Corporation (NYSE: BSX ) is ... Annual Healthcare Conference on May 6 in Boston ... president and chief financial officer, and Susie Lisa , ... and answer session regarding the company with the host analyst ... of the presentation and question and answer session will be ...
Breaking Medicine Technology:Pharmaceutical Industry Using New Technologies to Adjust Their Marketing and Research Approaches for Consumers 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Boston Scientific To Participate In The Deutsche Bank 40th Annual Healthcare Conference 2
... -- La Jolla,Pharmaceutical Company today announced updated interim ... Riquent(R) (abetimus,sodium), its drug candidate for systemic lupus ... previous,conclusion that there is a definitive and significant ... 900 mg doses of Riquent compared,with placebo (p=0.0001). ...
... N.J., March 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corporation's ... a potent payload in antibody conjugates for ... the Handbook of Therapeutic,Antibodies. , In a ... Susanna,Rybak, Ph.D. summarizes preclinical research indicating that ...
Cached Medicine Technology:La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
(Date:4/25/2015)... ME (PRWEB) April 26, 2015 ... Canadian based integrative healthcare event. The Integrative Healthcare ... place October 23-24, 2015 at the Sheraton Parkway ... Symposium Canada is one of the most anticipated ... clinically relevant, evidenced-based CME program. The event aims ...
(Date:4/25/2015)... April 25, 2015 The federal ... mesh lawsuits filed against C.R. Bard, Inc. continues ... Southern District of West Virginia. According to a ... was convened that day, after certain defendants submitted ... Complaint. The Order directed that any Preliminary Motions ...
(Date:4/25/2015)... Illinois (PRWEB) April 25, 2015 ... enrichment and wellness, management and operations, and sales ... Meeting and Exhibition scheduled to be held from ... , LeadingAge Illinois is the largest eldercare association ... providers of services for older adults, including senior ...
(Date:4/25/2015)... April 25, 2015 For thirteen years, the ... income protection education event in the nation! This year, on ... Plus Group, US to take DI Day on the road ... G. Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer ... Day reflects on the change by stating, "The first Twin ...
(Date:4/24/2015)... Foothill Ranch, California (PRWEB) April 24, 2015 ... that has a wide range of capabilities and services ... etc. , Ryadon's Quantity Discount Program will be ... ) as follows: , Order 4-19: Receive 10% discount ... Can Benefit by Using the Drawer Slides Products, ...
Breaking Medicine News(10 mins):Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... from the University of Hull has told the British Psychological ... eating chocolate, lazing in front of the television, or going ... could make them more susceptible to disease.Those on the other ... to fight off infection.// ,Researchers asked 30 students ...
... a new gel, which works in a similar way to ... stomach each day, is being tested in four countries world-wide.For ... popping the contraceptive pill. But now there's a new option ... Association says "The gel is like any other gel, but ...
... in the devastated NewYork of America nor in the Afghanistan! It ... And who are the warring parties? They are the pharmaceutical industry ... Chemists Association. The latter is a member body of over 5,000 ... R Shah. // ,It is a classic case of ...
... Researchers in the US have found that genes contribute ... smoking. Chronic obstructive pulmonary disease (COPD), the name given ... because it leads to increasing shortness of breath. It's ... is a major cause of the problem.// ...
... the brain helps people recognise themselves in a picture, ... Deaconess Medical Center in Boston report their findings in ... a growing body of evidence that demonstrates the right ... self-awareness may provide unique insights into consciousness and doctors ...
... People who drink and smoke have to drink more ... greater risk of damage to their brains, livers and hearts, ... reduces blood alcohol levels in rats, which are considered a ... they will end up drinking more alcohol to get an ...
Cached Medicine News:Health News:The right is responsible 2
Straight shafts 4 mm platform. Wide serrated handle with dull finish. Platform angled 45 degrees....
Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
Double-ended. 10 mm sickle shaped blade. 27 mm blunt, curved double-edged blade....
Fixed smooth rod which slides on skin. Designated most popular model or size....
Medicine Products: